Topics
High-grade gliomas | Treatment | Targeted therapy | Vorasidenib
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Vorasidenib
Dipasquale A, Giordano P, Bosio A, Wijnenga MMJ, Giordano L,
Losurdo A, Persico P, Padovan M, Viggiano A, Catapano G, Geurts M,
Pessina F, Santoro A, Lombardi G, Simonelli M.
Reasons
driving choice and clinical course of patients with CNS WHO grade
3 IDH mutant glioma receiving vorasidenib after surgery: a pilot
experience.
J
Neurooncol. 2026 Jan 28;176(3):186. doi:
10.1007/s11060-026-05439-0. PMID:
41604034. Observational study˰
ˍ